(Reuters) -German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.

Merck now expects mid-term annual organic sales growth in the low- to mid single-digit percentage range for its healthcare business, having guided for “slight growth” last year. It expects mid-to-high single-digit percentage growth for Life Science, after guiding for 7% to 9% last year.

For the group, Merck is now targeting mid-term annual organic sales growth in the mid single-digit percentage range.

PANDEMIC ASSUMPTIONS FAIL TO MATERIALIZE

The company also confirmed that it is aiming to achieve net sales between around 20.5 to 21.7 billion euros in 2025, a target it has cut twice this year.

This is far b

See Full Page